Because of the ongoing Covid-19 quarantine all portrait sessions are cancelled.

The global search for effective COVID-19 treatments brought renewed attention to older drugs, including ivermectin. Early studies and anecdotal reports suggested potential benefits of ivermectin for the treatment of COVID-19, leading to waves of public interest and controversy. Researchers and regulatory agencies faced challenges balancing the urgent need for therapies with the necessity of rigorous clinical evidence. Debates unfolded worldwide as some clinicians advocated for its use, while others cautioned against premature adoption without robust data. This period highlighted both the complexity of pandemic decision-making and the speed with which information—sometimes conflicting—could influence public perception and healthcare practice.